NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 313 filers reported holding NOVOCURE LTD in Q4 2022. The put-call ratio across all filers is 1.54 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $438,117 | -90.8% | 27,128 | -76.5% | 0.00% | -90.0% |
| Q2 2023 | $4,781,879 | -37.8% | 115,226 | -9.8% | 0.03% | -36.2% |
| Q1 2023 | $7,682,524 | -22.8% | 127,744 | -5.9% | 0.05% | -13.0% |
| Q4 2022 | $9,956,749 | -21.3% | 135,743 | -18.5% | 0.05% | -15.6% |
| Q3 2022 | $12,651,000 | +20.2% | 166,502 | +9.9% | 0.06% | +42.2% |
| Q2 2022 | $10,527,000 | -6.8% | 151,470 | +11.1% | 0.04% | -2.2% |
| Q1 2022 | $11,291,000 | +51.3% | 136,280 | +37.1% | 0.05% | +7.0% |
| Q4 2021 | $7,463,000 | -33.2% | 99,401 | +3.4% | 0.04% | -29.5% |
| Q3 2021 | $11,165,000 | -47.9% | 96,106 | -0.6% | 0.06% | -55.8% |
| Q2 2021 | $21,437,000 | – | 96,642 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nordwand Advisors, LLC | 1,515,000 | $24,467,250 | 4.85% |
| Invus Financial Advisors, LLC | 350,884 | $5,666,777 | 3.55% |
| Deep Track Capital, LP | 2,500,000 | $40,375,000 | 1.56% |
| TANG CAPITAL MANAGEMENT LLC | 492,100 | $7,947,415 | 1.12% |
| Palo Alto Investors LP | 660,275 | $10,663,441 | 1.01% |
| Taylor Frigon Capital Management LLC | 91,435 | $1,476,675 | 0.82% |
| Soleus Capital Management, L.P. | 344,100 | $5,557,215 | 0.51% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 74,000 | $1,193,620 | 0.40% |
| Symmetry Investments LP | 92,658 | $1,496 | 0.31% |
| SEVEN EIGHT CAPITAL, LP | 137,721 | $2,224,194 | 0.26% |